Cambridge, Mass., USA - November 8, 2010, Cambridge, Mass., USA - Infinity Pharmaceuticals, Inc. announced that it has named Pedro Santabarbara as chief medical officer and Elizabeth G. Trehu as vice president, product development and medical affairs.
Article continues below
Dr. Santabarbara joins Infinity following five years with PharmaMar, where he most recently led the development and approval of Yondelis® (trabectedin). Prior to PharmaMar, he served as vice president of clinical research oncology at OSI Pharmaceuticals, Inc. where he led the successful approval of Tarceva® (erlotinib).
Before joining OSI, Dr. Santabarbara led development activities for Campath® (alemtuzumab) at ILEX Oncology, Inc. He was also employed at Rhone Poulenc Rorer where he led the North American clinical development of Taxotere® (docetaxel), which he drove to approval in breast cancer and designed the strategy for non-small cell lung cancer. He also contributed to the development of Taxol® (paclitaxel) while at Bristol-Myers Squibb. Dr. Santabarbara's experience also includes 14 years in research and clinical practice. He holds a M.D. and Ph.D. from University of Barcelona, School of Medicine.
Dr. Trehu joins Infinity following four years at Genzyme Corporation, where she began as vice president of oncology global medical affairs and most recently held the position of vice president and general manager, hematology with global responsibility for Clolar® (clofarabine), Campath® and Fludara® (fludarabine). From 2002 to 2006, she held positions of increasing responsibility in medical affairs functions at Millennium Pharmaceuticals, principally in support of Velcade® (bortezomib).
Dr. Trehu's career prior to industry included laboratory and clinical research in immunotherapy of cancer as an assistant professor at Tufts University School of Medicine and several years in private practice as a hematologist-oncologist at the Jordan Hospital Club Cancer Center. She holds a M.D. from New York University School of Medicine and an A.B. from Princeton University. ■